A61P 39/00
General protective or antinoxious agents
A61P39/00 (General protective or antinoxious agents) appears on 6,123 US grants and 9,574 published applications in this corpus.
Search patents in A61P- Granted patents
- 6,123
- Published applications
- 9,574
- Assignees
- 3,827
- Inventors
- 17,499
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 4 | 0 |
| 1978 | 4 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 2 | 0 |
| 1982 | 17 | 0 |
| 1983 | 8 | 0 |
| 1984 | 2 | 0 |
| 1985 | 4 | 0 |
| 1986 | 8 | 0 |
| 1987 | 8 | 0 |
| 1988 | 14 | 0 |
| 1989 | 14 | 0 |
| 1990 | 10 | 0 |
| 1991 | 24 | 0 |
| 1992 | 12 | 0 |
| 1993 | 14 | 0 |
| 1994 | 20 | 0 |
| 1995 | 18 | 0 |
| 1996 | 40 | 0 |
| 1997 | 64 | 0 |
| 1998 | 75 | 0 |
| 1999 | 101 | 0 |
| 2000 | 92 | 0 |
| 2001 | 112 | 35 |
| 2002 | 141 | 183 |
| 2003 | 150 | 352 |
| 2004 | 140 | 364 |
| 2005 | 109 | 386 |
| 2006 | 149 | 375 |
| 2007 | 127 | 382 |
| 2008 | 170 | 438 |
| 2009 | 169 | 451 |
| 2010 | 267 | 548 |
| 2011 | 246 | 598 |
| 2012 | 329 | 537 |
| 2013 | 356 | 503 |
| 2014 | 385 | 477 |
| 2015 | 378 | 473 |
| 2016 | 319 | 455 |
| 2017 | 342 | 445 |
| 2018 | 314 | 392 |
| 2019 | 257 | 363 |
| 2020 | 239 | 309 |
| 2021 | 202 | 341 |
| 2022 | 175 | 286 |
| 2023 | 127 | 247 |
| 2024 | 157 | 272 |
| 2025 | 126 | 214 |
| 2026 | 78 | 148 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Honeybee antidote composition6 Oct 2026US 12,751,933 B2Andong National University Industry-Academic Cooperation Foundation
- Antioxidant and antiviral compositions and methods6 Oct 2026US 12,751,971 B2Mayo Foundation for Medical Education and Research
- Probiotic Bacillus compositions and methods of use29 Sep 2026US 12,746,261 B2BiomEdit, Inc.
- Spinning solution, and alginate fiber comprising cannabidiol, method for producing the same, and use thereof22 Sep 2026US 12,740,946 B2Pell Bio-Med Technology Co., Ltd.
- Compositions and methods using at least one glycine or derivative thereof and at least one large neutral amino acid and/or cationic amino acid or precursor thereof22 Sep 2026US 12,740,958 B2Societe des Produits Nestle S. A.
- Perfluorocarbon compositions, systems, and methods for ischemic, inflammatory, infectuous, transplant, and other medical conditions8 Oct 2026US 2026/0306422 A1
- Compositions and methods for reducing blood ethanol concentration through alcohol dehydrogenase and acetaldehyde scavengers8 Oct 2026US 2026/0306589 A1Goa Therapeutics Corporation
- Uses of Adrenalone to Manage Cardiotoxicity or Cardiovascular Disorders1 Oct 2026US 2026/0294845 A1Children's Healthcare of Atlanta, Inc.
- Uses of super-oxide dismutase supplements1 Oct 2026US 2026/0295019 A1
- Amino acid-derived ceramide, synthesis method therefor and use thereof1 Oct 2026US 2026/0297018 A1Shenzhen Dikeman Biotechnology Co., Ltd.
Most cited
By later US patents
- Human monoclonal antibodies to programmed death ligand 1 (PD-L1)628US 7,943,743 B2Medarex, Inc. · 2011
- Treatment of damaged bone marrow and dosage units therefor585US 4,938,949 AUniversity of New York · 1990
- Human antibodies that bind human TNF.alpha.451US 6,090,382 ABASF SE · 2000
- Tamper-resistant oral opioid agonist formulations343US 6,696,088 B2Euro-Celtique S. A. · 2004
- Human antibodies that bind human TNFα308US 6,258,562 B1BASF SE · 2001